Eli Lilly and Co LLY

Mr. David A. Ricks, Chair, President, and Chief Executive Officer (CEO) (since 2017). CAREER HIGHLIGHTS: Eli Lilly and Company: Chair, President, and Chief Executive Officer (2017 - present), Senior Vice President and President, Lilly Bio-Medicines (2012 - 2016), President, Lilly USA (2009 - 2012), Served in various marketing, sales and international leadership roles (1996 - 2009), including: As President and General Manager of Lilly China, As General Manager of Lilly Canada. OTHER HIGHLIGHTS: Director, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA); Director, Pharmaceutical Research and Manufacturers of America (PhRMA); Member, U.S. Patent and Trademark Office Council for Inclusive Innovation; Director and executive committee member, Central Indiana Corporate Partnership; Director, The Business Roundtable; Trustee, Purdue University Board of Trustees. Other Public Boards: Adobe Inc.

Mr. Daniel Skovronsky, Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories (since 2025). Prior to assuming his current role, Dr. Skovronsky served as Executive Vice President, Chief Scientific Officer, and President, Lilly Research Laboratories and Lilly Immunology since 2024. Dr. Skovronsky has held other leadership roles with Lilly, including as chief medical officer, senior vice president, clinical and product development and vice president, diabetes research. Dr. Skovronsky has 15 years of service with Lilly.

Mr. Jacob S. Van Naarden, Executive Vice President and President, Lilly Oncology (since 2021). Previously, Mr. Van Naarden served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has six years of service with Lilly.

Mr. Lucas Montarce, Executive Vice President and Chief Financial Officer (since 2024). Most recently, Mr. Montarce served as the president and general manager of Lilly's Spain, Portugal, and Greece hub, a position he assumed in 2024. Previously Mr. Montarce was group vice president, controller and chief financial officer of Lilly Research Laboratories, vice president, finance and chief financial officer, Lilly International, and vice president, finance and global chief financial officer, Elanco Health. Mr. Montarce has 24 years of service with Lilly.

Dr. Kaelin, CAREER HIGHLIGHTS Harvard Medical School Sidney Farber Professor of Medicine (2018 - present) Professor of Medicine (2002 - 2018) Dana-Farber Cancer Institute and Brigham and Women's Hospital Professor (2002 - present) Howard Hughes Medical Institute Investigator (2002 - present) Assistant Investigator (1998 - 2002) OTHER HIGHLIGHTS Recipient of numerous prizes and honors, including: Nobel Prize in Physiology or Medicine Albert Lasker Basic Medical Research Award Canada Gairdner International Award Wiley Prize in Biomedical Sciences from the Rockefeller University Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center; Member, National Academy of Medicine; National Academy of Sciences; American College of Physicians; Association of American Physicians; American Society of Clinical Investigation; American Academy of Arts and Sciences; American Philosophical Society.

Mr. Juan R. Luciano, CAREER HIGHLIGHTS Archer-Daniels-Midland Company, a global food processing and commodities-trading company Chairman (2016 - present) Chief Executive Officer and President (2015 - present) President and Chief Operating Officer (2014 - 2015) The Dow Chemical Company, a multinational chemical company Executive Vice President and President, Performance Division (2010 - 2011) OTHER HIGHLIGHTS Alternate director, Wilmar International Director, Intersect Illinois Director, Rush University Medical Center Member, The Business Roundtable,Member, Civic Committee at the Commercial Club of Chicago Member, Economic Club of Chicago. Other Public Boards: Archer-Daniels-Midland Company.

Ms. Gabrielle Sulzberger,CAREER HIGHLIGHTS Teneo, a global CEO advisory firm Chair of Global ESG Advisory (2021 - present) Two Sigma Impact, a private equity firm based in New York, New York Senior Advisor (2021 - 2023) Centerbridge Partners, a multidisciplinary investment firm Senior Advisor (2021 - present) Rustic Canyon/Fontis Partners L.P., a private equity firm based in California General Partner (2005 - 2018) OTHER HIGHLIGHTS Director or trustee of the following not-for-profit organizations: Metropolitan Museum of Art Ford Foundation Trinity Church Wall Street Sesame Street Workshop Former director, board chair and audit committee chair, Whole Foods Market, Inc. Other Public Boards: Mastercard Incorporated. Recent Prior Public Boards: Warby Parker Inc; Cerevel Therapeutics Holdings, Inc; Brixmor Property Group Inc.

Mr. Alvarez CAREER HIGHLIGHTS Advent International Corporation, a leading global private equity firm Operating Partner (2017 - present) Skylark Co., Ltd., a leading restaurant operator in Japan Chairman of the board (2013 - 2018) McDonald's Corporation, a leading food service retailer President and Chief Operating Officer (2006 - 2009) OTHER HIGHLIGHTS Member, University of Miami President's Council. Other Public Boards:Lowe's Companies, Inc;Traeger, Inc; First Watch Restaurant Group, Inc. (Chair). Recent Prior Public Boards: Dunkin' Brands Group, Inc.

Dr. Baicker , CAREER HIGHLIGHTS University of Chicago Provost (2023 - present) Emmett Dedmon Professor, Harris School of Public Policy (2017 - present) Dean of the Harris School of Public Policy (2017 - 2023) Harvard University C. Boyden Gray Professor of Health Economics (2014 - 2017) Department of Health Policy and Management, chair (2014 - 2016) Harvard T.H. Chan School of Public Health (primary) Harvard Kennedy School of Government (secondary) National Bureau of Economic Research Research Associate, Health Care and Public Economics Programs (2007 - present) Faculty Research Fellow, Public Economics Program (2001 - 2005) Council of Economic Advisers, Executive Office of the President Member, confirmed by U.S. Senate (2005 - 2007) OTHER HIGHLIGHTS Panel of Health Advisers to the Congressional Budget Office Advisory Board of the National Institute for Health Care Management Editorial Board of Health Affairs, JAMA Health Forum Trustee of the Mayo Clinic Member of the National Academy of Medicine, the National Academy of Social Insurance, the Council on Foreign Relations, and the American Academy of Arts and Sciences. Recent Prior Public Boards: HMS Holdings Corp.

Dr. Mary Lynne Hedley,PhD,CAREER HIGHLIGHTS Broad Institute of Harvard and MIT Senior Scientific Fellow (2021 - present) Third Rock Ventures, a leading healthcare venture capital firm Venture Partner (2023 - present) GlaxoSmithKline plc, a leading global pharmaceutical company Member of executive research and development team; led integration efforts for TESARO acquisition (2019 - 2020) TESARO, Inc., a company focused on the development and global commercialization of oncology therapeutics (acquired by GlaxoSmithKline plc in 2019) President and Chief Operating Officer (2010 - 2019) Abraxis BioScience, Inc., a biotechnology company (acquired by Celgene Corporation in 2010 Executive Vice President and Chief Science Officer (2009 - 2010) OTHER HIGHLIGHTS Member, American Association of Immunologists; American Association for Advancement of Science; American Society of Clinical Oncology; American Association of Cancer Research Advisory board, Boston Museum of Science and chair, Life Science Committee. Other Public Boards: VEEVA Systems Inc; Centessa Pharmaceuticals plc. Recent Prior Public Boards: Millendo Therapeutics, Inc.

Mr. Diogo Rau, Executive Vice President and Chief Information and Digital Officer (since 2021). Prior to joining Lilly, Mr. Rau was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey & Company. Mr. Rau has five years of service with Lilly.

Mr. Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities (since 2025). Mr. Yuffa has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly International. Previously, he served as senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer. Mr. Yuffa has 29 years of service with Lilly.

Mr. Eric Dozier, Executive Vice President, Chief People Officer (since 2022). Previously, Mr. Dozier held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo Lilly, and vice president, global ethics and compliance officer. Mr. Dozier has 28 years of service with Lilly.

Patrik Jonsson, Executive Vice President and President, Lilly International (since 2025). Mr. Jonsson has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly Cardiometabolic Health and Lilly USA. Previously, he served as Executive Vice President and President, Lilly Immunology and Lilly USA, and Chief Customer Officer, senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 35 years of service with Lilly.

Ms. Melissa Seymour, Executive Vice President, Global Quality (since 2024). Prior to joining Lilly, Ms. Seymour was the chief quality officer for Bristol Myers Squibb from 2022 to 2024. Before joining Bristol Myers Squibb, Ms. Seymour was also the chief quality officer at Biogen. Ms. Seymour has two years of service with Lilly.

Mr. Edgardo Hernandez, Executive Vice President and President, Manufacturing Operations (since 2021). Previously, Mr. Hernandez held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has 21 years of service with Lilly.

The board of directors elected Donald A. Zakrowski as vice president, finance and chief accounting officer effective November 1, 2012. Mr. Zakrowski has served as the senior director of Lilly's global finance shared service centers since 2010. Prior to that, Mr. Zakrowski served as senior director of accounting operations and reporting. He joined Lilly in 2001 as a senior financial consultant and has had responsibility for a broad range of financial and accounting activities at the company. Prior to joining Lilly, Mr. Zakrowski spent ten years in public accounting at PricewaterhouseCoopers.

Kenneth Custer, Ph.D., Executive Vice President and President, Lilly Cardiometabolic Health (since 2025). Dr. Custer has held various leadership roles with Lilly, including most recently, as president and general manager of Lilly Canada. Previously, he served as senior vice president and head of corporate business development. Dr. Custer has 17 years of service with Lilly.

On November 18, 2025, the Board of Directors of Eli Lilly and Company elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025. Dr. Bertozzi, 59, is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi will serve on both the Board's Science and Technology Committee and the Ethics and Compliance Committee and will stand for election by Company shareholders at the Company's annual meeting in May 2026.